Skip to main
PRAX
PRAX logo

PRAX Stock Forecast & Price Target

PRAX Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 25%
Hold 8%
Sell 8%
Strong Sell 0%

Bulls say

Praxis Precision Medicine has exhibited substantial growth in research and development (R&D) expenses, with a striking 206.1% year-over-year increase, highlighting the company's commitment to advancing its clinical-stage product candidates, including ulixacaltamide and vormatrigine. The firm is poised for potential growth as the peak market share for vormatrigine is anticipated to rise based on its favorable clinical profile, which could enhance patient treatment persistence and drive earlier usage in therapeutic lines. Additionally, with a robust financial position and plans for multiple studies into 2025, Praxis is well-positioned to capitalize on increasing diagnosis and treatment rates in conditions like essential tremor, which may expand its patient population and contribute to long-term growth.

Bears say

Praxis Precision Medicine is facing significant challenges that could adversely impact its stock performance, primarily stemming from clinical and regulatory setbacks, which have already led to the halting of the ulixacaltamide study due to concerns regarding its efficacy. The company's financial situation is further strained by an operating loss that widened to $64.0 million in the latest quarter, exceeding prior estimates, while the removal of ulixacaltamide sales from valuation models sharply reduced expected revenue. Additionally, the reliance on the success of its pipeline products in a competitive landscape raises concerns that even if approved, these therapies may struggle to gain market acceptance, leading to disappointing sales.

PRAX has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 25% recommend Buy, 8% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Praxis Precision Medicines and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Praxis Precision Medicines (PRAX) Forecast

Analysts have given PRAX a Buy based on their latest research and market trends.

According to 12 analysts, PRAX has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Praxis Precision Medicines (PRAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.